Johnson & Johnson (JNJ.CL)
| Previous close | 602,300.00 |
| Open | 0.00 |
| Bid | 602,300.00 x 800 |
| Ask | 637,300.00 x N/A |
| Day's range | 602,300.00 - 602,300.00 |
| 52-week range | 602,300.00 - 602,300.00 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- PR Newswire
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable responses, irrespective of whether they had received prior T-cell redirection therapy.1 These data, featured in a poster presentation at the 2024 European
- Business Wire
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J., June 04, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 17th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s execut
- Business Wire
Johnson & Johnson Completes Acquisition of Shockwave Medical
NEW BRUNSWICK, N.J., May 31, 2024--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
